2022 07 08 16 10 0843 Research Money 400

OpGen on Friday said it anticipates preliminary revenues of $1 million for the second quarter, which would be an increase of 25% from $800,000 in Q2 2021.

As of June 30, OpGen had approximately $16.6 million in cash.

Among the highlights for the second quarter, the firm said that it signed the first commercial customer contract for the Acuitas AMR Gene Panel and expanded a distribution agreement with Menarini. Moreover, its subsidiary Ares Genetics extended its collaboration agreement with Sandoz on digital solutions for fighting antimicrobial resistance.

Page 1 of 35
Next Page